{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T04:03:37Z","timestamp":1780113817393,"version":"3.54.0"},"reference-count":36,"publisher":"Japanese Circulation Society","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2026,5,25]]},"DOI":"10.1253\/circj.cj-25-1183","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T22:10:32Z","timestamp":1777414232000},"page":"661-670","source":"Crossref","is-referenced-by-count":0,"title":["Mac-2 Binding Protein Glycosylation Isomer (M2BPGi) Reflects Global Pathophysiology and Predicts All-Cause Morbidity and Mortality in Patients With Fontan Circulation"],"prefix":"10.1253","volume":"90","author":[{"given":"Hideo","family":"Ohuchi","sequence":"first","affiliation":[{"name":"Department of Paediatric Cardiology, National Cerebral and Cardiovascular Center"},{"name":"Adult Congenital Heart Disease Center, National Cerebral and Cardiovascular Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aki","family":"Mori","sequence":"additional","affiliation":[{"name":"Adult Congenital Heart Disease Center, National Cerebral and Cardiovascular Center"},{"name":"Department of Medical Safety, National Cerebral and Cardiovascular Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihito","family":"Morimoto","sequence":"additional","affiliation":[{"name":"Department of Paediatric Cardiology, National Cerebral and Cardiovascular Center"},{"name":"Adult Congenital Heart Disease Center, National Cerebral and Cardiovascular Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Paediatric Cardiology, National Cerebral and Cardiovascular Center"},{"name":"Adult Congenital Heart Disease Center, National Cerebral and Cardiovascular Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuto","family":"Fujimoto","sequence":"additional","affiliation":[{"name":"Department of Paediatric Cardiology, National Cerebral and Cardiovascular Center"},{"name":"Adult Congenital Heart Disease Center, National Cerebral and Cardiovascular Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Iwasa","sequence":"additional","affiliation":[{"name":"Department of Paediatric Cardiology, National Cerebral and Cardiovascular Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isao","family":"Shiraishi","sequence":"additional","affiliation":[{"name":"Department of Paediatric Cardiology, National Cerebral and Cardiovascular Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Kurosaki","sequence":"additional","affiliation":[{"name":"Department of Paediatric Cardiology, National Cerebral and Cardiovascular Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michikazu","family":"Nakai","sequence":"additional","affiliation":[{"name":"Clinical Research Support Center, University of Miyazaki Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Rychik J, Atz AM, Celermajer DS, Deal BJ, Gatzoulis MA, Gewillig MH, et al. Evaluation and management of the child and adult with Fontan circulation: A scientific statement from the American Heart Association. <i>Circulation<\/i> 2019; 140: e234\u2013e284, doi:10.1161\/CIR.0000000000000696.","DOI":"10.1161\/CIR.0000000000000696"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Cao JY, Wales KM, d\u2019Udekem Y, Celermajer DS, Cordina R, Majumdar A. Prevalence, risk factors, and prognosis for Fontan-associated liver disease: A systematic review and exploratory meta-analysis. <i>JACC Adv<\/i> 2025; 4: 101694, doi:10.1016\/j.jacadv.2025.101694.","DOI":"10.1016\/j.jacadv.2025.101694"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Martin de Miguel I, Kamath PS, Egbe AC, Jain CC, Cetta F, Connolly HM, et al. Haemodynamic and prognostic associations of liver fibrosis scores in Fontan-associated liver disease. <i>Heart<\/i> 2023; 109: 619\u2013625, doi:10.1136\/heartjnl-2022-321435.","DOI":"10.1136\/heartjnl-2022-321435"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. Ohuchi H, Hayama Y, Nakajima K, Kurosaki K, Shiraishi I, Nakai M. Incidence, predictors, and mortality in patients with liver cancer after Fontan operation. <i>J Am Heart Assoc<\/i> 2021; 10: e016617, doi:10.1161\/JAHA.120.016617.","DOI":"10.1161\/JAHA.120.016617"},{"key":"5","doi-asserted-by":"publisher","unstructured":"10. Kamada Y, Sumida Y, Takahashi H, Fujii H, Miyoshi E, Nakajima A, et al. Utility of Mac-2 binding protein glycosylation isomer as an excellent biomarker for the prediction of liver fibrosis, activity, and hepatocellular carcinoma onset: An expert review. <i>J Gastroenterol<\/i> 2025; 60: 10\u201323, doi:10.1007\/s00535-024-02179-8.","DOI":"10.1007\/s00535-024-02179-8"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Gong S, Yu X, Li Q, Chen M, Yu S, Yang S. Evaluation of Mac-2 binding protein glycosylation isomer as a diagnostic marker for staging liver fibrosis: A meta-analysis. <i>PeerJ<\/i> 2024; 12: e17611, doi:10.7717\/peerj.17611.","DOI":"10.7717\/peerj.17611"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Pham TTT, Ho DT, Phan HT, Nguyen TB, Nguyen KM. Assessing the role of Mac-2 binding protein glycosylation isomer in management of chronic hepatitis B. <i>World J Hepatol<\/i> 2025; 17: 106916, doi:10.4254\/wjh.v17.i5.106916.","DOI":"10.4254\/wjh.v17.i5.106916"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8. Uojima H, Yamasaki K, Sugiyama M, Kage M, Ishii N, Shirabe K, et al. Quantitative measurements of Mac-2 binding protein glycosylation isomer depend on liver fibrosis and inflammation. <i>J Gastroenterol<\/i> 2024; 59: 598\u2013608, doi:10.1007\/s00535-024-02100-3.","DOI":"10.1007\/s00535-024-02100-3"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Chen CH, Wang JH, Lai HC, Hu TH, Hung CH, Lu SN, et al. Mac-2 binding protein glycosylation isomer predicts hepatocellular carcinoma and mortality in chronic hepatitis B. <i>Am J Cancer Res<\/i> 2024; 14: 2465\u20132477, doi:10.62347\/DAGB7277.","DOI":"10.62347\/DAGB7277"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Kamada Y, Sumida Y, Takahashi H, Fujii H, Miyoshi E, Nakajima A, et al. Utility of Mac-2 binding protein glycosylation isomer as an excellent biomarker for the prediction of liver fibrosis, activity, and hepatocellular carcinoma onset: An expert review. <i>J Gastroenterol<\/i> 2025; 60: 10\u201323, doi:10.1007\/s00535-024-02179-8.","DOI":"10.1007\/s00535-024-02179-8"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11. Ohuchi H, Yasuda K, Hasegawa S, Miyazaki A, Takamuro M, Yamada O, et al. Influence of ventricular morphology on aerobic exercise capacity after the Fontan operation. <i>J Am Coll Cardiol<\/i> 2001; 37: 1967\u20131974, doi:10.1016\/S0735-1097(01)01266-9.","DOI":"10.1016\/S0735-1097(01)01266-9"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12. Uojima H, Nakabayashi K, Yamasaki K, Sugiyama M, Ishii N, Shirabe K, et al. New chemiluminescent enzyme immunoassay for quantitative measurement of Mac-2 binding protein glycosylation isomer. <i>J Gastroenterol<\/i> 2023; 58: 1252\u20131260, doi:10.1007\/s00535-023-02043-1.","DOI":"10.1007\/s00535-023-02043-1"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13. Li Q, Ren X, Lu C, Li W, Huang Y, Chen L. Evaluation of APRI and FIB-4 for noninvasive assessment of liver fibrosis in HBeAg-negative chronic hepatitis B. <i>Medicine (Baltimore)<\/i> 2017; 96: e6336, doi:10.1097\/MD.0000000000006336.","DOI":"10.1097\/MD.0000000000006336"},{"key":"14","doi-asserted-by":"publisher","unstructured":"14. Schreiner AD, Moran WP, Zhang J, Livingston S, Marsden J, Mauldin PD, et al. Association of Fibrosis-4 index scores with severe liver outcomes in primary care. <i>J Gen Intern Med<\/i> 2022; 37: 3266\u20133274, doi:10.1007\/s11606-021-07341-z.","DOI":"10.1007\/s11606-021-07341-z"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15. Liguori A, Zoncap\u00e8 M, Casazza G, Easterbrook P, Tsochatzis EA. Staging liver fibrosis and cirrhosis using non-invasive tests in people with chronic hepatitis B to inform WHO 2024 guidelines: A systematic review and meta-analysis. <i>Lancet Gastroenterol Hepatol<\/i> 2025; 10: 332\u2013349, doi:10.1016\/S2468-1253(24)00437-0.","DOI":"10.1016\/S2468-1253(24)00437-0"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16. Rosenberg HK, Markowitz RI, Kolberg H, Park C, Hubbard A, Bellah RD. Normal splenic size in infants and children: Sonographic measurements. <i>AJR Am J Roentgenol<\/i> 1991; 157: 119\u2013121, doi:10.2214\/ajr.157.1.2048509.","DOI":"10.2214\/ajr.157.1.2048509"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17. Ohuchi H, Takei K, Muneuchi J, Kasahara S, Ishikawa Y, Muraji S, et al. Unplanned hospitalization due to all-cause morbidity and its real-world management practices in patients with Fontan circulation. <i>J Am Heart Assoc<\/i> 2025; 14: e044374, doi:10.1161\/JAHA.125.044374.","DOI":"10.1161\/JAHA.125.044374"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18. Ohuchi H, Negishi J, Hayama Y, Sasaki O, Taniguchi Y, Noritake K, et al. Hyperuricemia reflects global Fontan pathophysiology and associates with morbidity and mortality in patients after the Fontan operation. <i>Int J Cardiol<\/i> 2015; 184: 623\u2013630, doi:10.1016\/j.ijcard.2015.02.026.","DOI":"10.1016\/j.ijcard.2015.02.026"},{"key":"19","doi-asserted-by":"publisher","unstructured":"19. Royston P, Sauerbrei W. Stability of multivariable fractional polynomial models with selection of variables and transformations: A bootstrap investigation. <i>Stat Med<\/i> 2003; 22: 639\u2013659, doi:10.1002\/sim.1310.","DOI":"10.1002\/sim.1310"},{"key":"20","doi-asserted-by":"publisher","unstructured":"20. Mueller C, McDonald K, de Boer RA, Maisel A, Cleland JGF, Kozhuharov N, et al. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. <i>Eur J Heart Fail<\/i> 2019; 21: 715\u2013731, doi:10.1002\/ejhf.1494.","DOI":"10.1002\/ejhf.1494"},{"key":"21","doi-asserted-by":"publisher","unstructured":"21. Nah EH, Cho S, Kim S, Kim HS, Cho HI. Diagnostic performance of Mac-2 binding protein glycosylation isomer (M2BPGi) in screening liver fibrosis in health checkups. <i>J Clin Lab Anal<\/i> 2020; 34: e23316, doi:10.1002\/jcla.23316.","DOI":"10.1002\/jcla.23316"},{"key":"22","doi-asserted-by":"publisher","unstructured":"22. Cai X, Li Z, Zhang Q, Qu Y, Xu M, Wan X, et al. CXCL6\u2013EGFR-induced Kupffer cells promote hepatic stellate cell activation in liver fibrosis. <i>J Cell Mol Med<\/i> 2018; 22: 5050\u20135061, doi:10.1111\/jcmm.13787.","DOI":"10.1111\/jcmm.13787"},{"key":"23","doi-asserted-by":"publisher","unstructured":"23. Kuno A, Ikehara Y, Tanaka Y, Ito K, Matsuda A, Sekiya S, et al. A serum \u201csweet-doughnut\u201d protein facilitates fibrosis evaluation and therapy assessment. <i>Sci Rep<\/i> 2013; 3: 1065, doi:10.1038\/srep01065.","DOI":"10.1038\/srep01065"},{"key":"24","doi-asserted-by":"publisher","unstructured":"24. Simonetto DA, Yang HY, Yin M, de Assuncao TM, Kwon JH, Hilscher M, et al. Chronic passive venous congestion drives hepatic fibrogenesis. <i>Hepatology<\/i> 2015; 61: 648\u2013659, doi:10.1002\/hep.27387.","DOI":"10.1002\/hep.27387"},{"key":"25","doi-asserted-by":"publisher","unstructured":"25. Ishii N, Araki K, Gantumur D, Fukushima R, Okuyama T, Seki T, et al. Mac-2 binding protein glycosylation isomer increases in obstructive jaundice. <i>Hepatol Res<\/i> 2025; 55: 1376\u20131384, doi:10.1111\/hepr.14236.","DOI":"10.1111\/hepr.14236"},{"key":"26","doi-asserted-by":"publisher","unstructured":"26. Copple BL, Bai S, Burgoon LD, Moon JO. Hypoxia-inducible factor-1\u03b1 regulates collagen deposition in hypoxic hepatic stellate cells. <i>Liver Int<\/i> 2011; 31: 230\u2013244, doi:10.1111\/j.1478-3231.2010.02347.x.","DOI":"10.1111\/j.1478-3231.2010.02347.x"},{"key":"27","doi-asserted-by":"publisher","unstructured":"27. Fan B, Meng L, Zheng X, Bai L, Du Y, Ding H, et al. Liraglutide inhibits proliferation of hepatic stellate cells. <i>Sci Rep<\/i> 2025; 15: 13360, doi:10.1038\/s41598-025-97872-w.","DOI":"10.1038\/s41598-025-97872-w"},{"key":"28","doi-asserted-by":"publisher","unstructured":"28. Hao Y, Song S, Li T, Zai Q, Ma N, Li Y, et al. Oxidative stress promotes liver fibrosis via microRNA-144. <i>Int J Biol Sci<\/i> 2024; 20: 2422\u20132439, doi:10.7150\/ijbs.92749.","DOI":"10.7150\/ijbs.92749"},{"key":"29","doi-asserted-by":"publisher","unstructured":"29. Shi YF, Fong CC, Zhang Q, Cheung PY, Tzang CH, Wu RS, et al. Hypoxia induces activation of human hepatic stellate cells. <i>FEBS Lett<\/i> 2007; 581: 203\u2013210, doi:10.1016\/j.febslet.2006.12.010.","DOI":"10.1016\/j.febslet.2006.12.010"},{"key":"30","doi-asserted-by":"publisher","unstructured":"30. Shah AH, Surendran A, Hassan-Tash P, Turnbull CN, Johnston N, Goodlett D, et al. Association of Fontan pathophysiology with plasma bile acids. <i>JACC Adv<\/i> 2025; 4: 101563, doi:10.1016\/j.jacadv.2024.101563.","DOI":"10.1016\/j.jacadv.2024.101563"},{"key":"31","doi-asserted-by":"publisher","unstructured":"31. Xu H, Fang F, Wu K, Song J, Li Y, Lu X, et al. Gut microbiota\u2013bile acid crosstalk regulates lipid metabolism. <i>Microbiome<\/i> 2023; 11: 262, doi:10.1186\/s40168-023-01709-5.","DOI":"10.1186\/s40168-023-01709-5"},{"key":"32","doi-asserted-by":"publisher","unstructured":"32. Ohuchi H, Asano R, Mori A, Ishibashi T, Motooka D, Nakai M, et al. Gut dysbiosis in patients with Fontan circulation. <i>J Am Heart Assoc<\/i> 2024; 13: e034538, doi:10.1161\/JAHA.124.034538.","DOI":"10.1161\/JAHA.124.034538"},{"key":"33","doi-asserted-by":"publisher","unstructured":"33. Ohuchi H, Negishi J, Hayama Y, Miike H, Suzuki D, Nakajima K, et al. Abnormal glucose metabolism in Fontan circulation. <i>Am Heart J<\/i> 2019; 216: 125\u2013135, doi:10.1016\/j.ahj.2019.07.013.","DOI":"10.1016\/j.ahj.2019.07.013"},{"key":"34","doi-asserted-by":"publisher","unstructured":"34. Lecointe J, Gan S, Tripathi D, Ichimura S, Clouthier KL, Kushwaha A, et al. Plasma proteomics of the Fontan circulation. <i>Circ Heart Fail<\/i> 2025; 18: e012136, doi:10.1161\/CIRCHEARTFAILURE.124.012136.","DOI":"10.1161\/CIRCHEARTFAILURE.124.012136"},{"key":"35","doi-asserted-by":"publisher","unstructured":"35. Guerrero-Chalela CE, Therrien J, Grossman Y, Guo L, Liu A, Marelli A. Severe Fontan-associated liver disease and its association with mortality. <i>J Am Heart Assoc<\/i> 2023; 12: e024034, doi:10.1161\/JAHA.121.024034.","DOI":"10.1161\/JAHA.121.024034"},{"key":"36","doi-asserted-by":"publisher","unstructured":"36. Emamaullee J, Khan S, Weaver C, Goldbeck C, Yanni G, Kohli R, et al. Non-invasive biomarkers of Fontan-associated liver disease. <i>JHEP Rep<\/i> 2021; 3: 100362, doi:10.1016\/j.jhepr.2021.100362.","DOI":"10.1016\/j.jhepr.2021.100362"}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/90\/6\/90_CJ-25-1183\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T03:21:50Z","timestamp":1780111310000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/90\/6\/90_CJ-25-1183\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.cj-25-1183","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]},"article-number":"CJ-25-1183"}}